期刊
STROKE
卷 53, 期 5, 页码 1460-1472出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.121.036948
关键词
blood-brain barrier; central nervous system; hemorrhage; inflammation; interleukin
资金
- National Institutes of Health (NIH) [R01NS090962, R01NS102395, R21NS109575]
Stroke is a significant clinical need with limited treatment options and a narrow therapeutic window. Inflammation after stroke can lead to secondary cell death, and stem cell therapy shows potential in reducing these inflammatory responses.
Stroke remains a significant unmet clinical need with few treatment options that have a very narrow therapeutic window, thereby causing massive mortality and morbidity in the United States and around the world. Accordingly, finding safe and effective novel treatments with a wider therapeutic window stands as an urgent need in stroke. The progressive inflammation that occurs centrally and peripherally after stroke serves as a unique therapeutic target to retard and even halt the secondary cell death. Stem cell therapy represents a potent approach that can diminish inflammation in both the stroke brain and periphery (eg, spleen), advancing a paradigm shift from a traditionally brain-focused therapy to treating stroke as a neurological disorder with a significant peripheral pathology. The purpose of this review article is to highlight the inflammation-mediated secondary cell death that plagues both brain and spleen in stroke and to evaluate the therapeutic potential of stem cell therapy in dampening these inflammatory responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据